logo

CSTL

Castle Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CSTL fundamentals

Castle Biosciences (CSTL) released its earnings on Nov 3, 2025: revenue was 83.00M (YoY -3.24%), beat estimates; EPS was -0.02 (YoY -125.00%), beat estimates.
Revenue / YoY
83.00M
-3.24%
EPS / YoY
-0.02
-125.00%
Report date
Nov 3, 2025
CSTL Earnings Call Summary for Q3,2025
  • $33B Market Launch: AdvanceAD-Tx targets 13.2M U.S. atopic dermatitis patients.
  • Revenue Growth: Q3 up 36% YoY, melanoma test hits record 10,459 reports.
  • Updated Guidance: 2025 revenue raised to $327M-$335M.
  • Cash Flow Strength: Positive net cash flow from operations.
  • Strategic Focus: Melanoma growth, TissueCypher expansion, FDA melanoma approval pursuit.
EPS
Revenue

Revenue & Expenses

CSTL has released its 2025 Q3 earnings report, with revenue of 83.04M, reflecting a YoY change of -3.19%, and net profit of -501.00K, showing a YoY change of -122.08%. The Sankey diagram below clearly presents CSTL's revenue sources and cost distribution.

Key Indicators

Castle Biosciences (CSTL) key financial stats and ratios, covering profitability, financial health, and leverage.
Castle Biosciences (CSTL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Castle Biosciences (CSTL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Castle Biosciences (CSTL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Castle Biosciences (CSTL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Castle Biosciences (CSTL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield